Michael DeBaun

(iStock)

VUMC part of new study validating curative therapy for sickle cell disease

Of 38 adults with severe SCD who participated in the study, more than 97% no longer required immunosuppressive therapy one year after the transplant.

International trial introduces another curative option for sickle cell disease 

The therapy, haploidentical bone marrow transplant with thiotepa and posttransplant cyclophosphamide, is as safe and more affordable than the recently FDA-approved myeloablative gene therapy and gene editing treatments.

Michael DeBaun receives Paragon Award from the Doris Duke Charitable Foundation

Vanderbilt’s Michael DeBaun, MD, MS, MPH, has received the Paragon Award for “Innovative Improvements to Clinical Care or Healthcare Delivery” from the Doris Duke Charitable Foundation (DDF).

Michael DeBaun, MD, MS, MPH

VUMC’s DeBaun elected president-elect of the American Pediatric Society

Vanderbilt’s Michael DeBaun, MD, MS, MPH, has been elected president-elect of the American Pediatric Society.

HBCU scholars program expanding enrollment

The James Puckette Carter Scholars Program, the result of a partnership between Meharry Medical College (MMC), Vanderbilt University Medical Center and the Burroughs Wellcome Fund (BWF), intended to increase the number of physicians who attended Historically Black Colleges and Universities (HBCUs) in health care, is expanding to double its enrollment capacity.

DeBaun’s mentoring honored by American Society of Hematology

Michael DeBaun, MD, MPH, has been awarded the American Society of Hematology’s 2019 ASH Mentor Award for his sustained and outstanding commitment to the training and career development of early career hematologists.

1 2